These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 12869802)

  • 21. Modelling neurodegenerative diseases in Drosophila: a fruitful approach?
    Muqit MM; Feany MB
    Nat Rev Neurosci; 2002 Mar; 3(3):237-43. PubMed ID: 11994755
    [TBL] [Abstract][Full Text] [Related]  

  • 22. What's new in...neurogenetics? Focus on neurodegenerative disorders.
    Suri M
    Eur J Paediatr Neurol; 2001; 5(6):221-4. PubMed ID: 11764180
    [No Abstract]   [Full Text] [Related]  

  • 23. Rodent models for dystonia research: characteristics, evaluation, and utility.
    Jinnah HA; Hess EJ; Ledoux MS; Sharma N; Baxter MG; Delong MR
    Mov Disord; 2005 Mar; 20(3):283-92. PubMed ID: 15641011
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Insights from mouse models into the molecular basis of neurodegeneration.
    Heintz N; Zoghbi HY
    Annu Rev Physiol; 2000; 62():779-802. PubMed ID: 10845111
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Transgenic mouse models of neurodegenerative disease caused by CAG/polyglutamine expansions.
    Bates GP; Davies SW
    Mol Med Today; 1997 Nov; 3(11):508-15. PubMed ID: 9430787
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Drosophila models of human neurodegenerative disease.
    Chan HY; Bonini NM
    Cell Death Differ; 2000 Nov; 7(11):1075-80. PubMed ID: 11139281
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Can flies help humans treat neurodegenerative diseases?
    Marsh JL; Thompson LM
    Bioessays; 2004 May; 26(5):485-96. PubMed ID: 15112229
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mouse models of human neurodegenerative disorders: requirements for medication development.
    Bloom FE; Reilly JF; Redwine JM; Wu CC; Young WG; Morrison JH
    Arch Neurol; 2005 Feb; 62(2):185-7. PubMed ID: 15710845
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Transcriptome profiling in neurodegenerative disease.
    Courtney E; Kornfeld S; Janitz K; Janitz M
    J Neurosci Methods; 2010 Nov; 193(2):189-202. PubMed ID: 20800617
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Increased Dickkopf-1 expression in transgenic mouse models of neurodegenerative disease.
    Rosi MC; Luccarini I; Grossi C; Fiorentini A; Spillantini MG; Prisco A; Scali C; Gianfriddo M; Caricasole A; Terstappen GC; Casamenti F
    J Neurochem; 2010 Mar; 112(6):1539-51. PubMed ID: 20050968
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Genes and the environment in neurodegeneration.
    Coppedè F; Mancuso M; Siciliano G; Migliore L; Murri L
    Biosci Rep; 2006 Oct; 26(5):341-67. PubMed ID: 17029001
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Behavioral phenotyping of mouse models of neurodegeneration.
    Dumont M
    Methods Mol Biol; 2011; 793():229-37. PubMed ID: 21913104
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Inflammation and susceptibility to neurodegeneration: the use of unbiased genetics to decipher critical regulatory pathways.
    Piehl F; Olsson T
    Neuroscience; 2009 Feb; 158(3):1143-50. PubMed ID: 18805461
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Promises and challenges in developing RNAi as a research tool and therapy for neurodegenerative diseases.
    Xia XG; Zhou H; Xu Z
    Neurodegener Dis; 2005; 2(3-4):220-31. PubMed ID: 16909029
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Validity of mouse models for the study of tissue transglutaminase in neurodegenerative diseases.
    Bailey CD; Graham RM; Nanda N; Davies PJ; Johnson GV
    Mol Cell Neurosci; 2004 Mar; 25(3):493-503. PubMed ID: 15033177
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Proteins and mutations: a new vision (molecular) of neurodegenerative diseases].
    Christen Y
    J Soc Biol; 2002; 196(1):85-94. PubMed ID: 12134639
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Brain banking for neurodegenerative diseases.
    Murphy DD; Ravina B
    Curr Opin Neurol; 2003 Aug; 16(4):459-63. PubMed ID: 12869803
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The ons and offs of inducible transgenic technology: a review.
    Yamamoto A; Hen R; Dauer WT
    Neurobiol Dis; 2001 Dec; 8(6):923-32. PubMed ID: 11741388
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Introduction to the special issue of brain structure and function on transgenic modeling of neurodegenerative disorders.
    Hof PR; Elder GA
    Brain Struct Funct; 2010 Mar; 214(2-3):89-90. PubMed ID: 20169361
    [No Abstract]   [Full Text] [Related]  

  • 40. Mouse models of neuronal ceroid lipofuscinoses: useful pre-clinical tools to delineate disease pathophysiology and validate therapeutics.
    Shacka JJ
    Brain Res Bull; 2012 May; 88(1):43-57. PubMed ID: 22502604
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.